MK-5172 (potassium salt) - CAS# 1206524-86-8 Catalog No.:M9690-10 blocking the pre- and postsynaptic

blocking the pre- and postsynaptic alpha-2 adrenoreceptors and causing an increased release of noradrenaline and dopamine

Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma

CAS Number: 154447-35-5

Smiles: C[C@]12O[C@H](C[C@]1(O)C(=O)OC)N1C3C4=C(C5CNC(=O)C=5C=3C3=CC=CC=C13)C1=CC=CC=C1N24

SHP2 is a nonreceptor protein tyrosine phosphatase (PTP) encoded by the PTPN11 gene involved in cell growth and differentiation via the MAPK signaling pathway

MK-5172 (potassium salt) - CAS# 1206524-86-8 Catalog No.:M9690-10 blocking the pre- and postsynapticGrazoprevir, also known as MK5172, is a drug approved for the treatment of hepatitis C. It was developed by Merck and completed Phase III trials, following promising results in Phase II when used in combination with the NS5A replication complex inhibitor elbasvir, either with or without ribavirin. Grazoprevir is a second generation hepatitis C virus protease inhibitor acting at the NS3 4a protease targets. It has good activity against a range of HCV